Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

NASDAQ:ORGO - US68621F1021 - Common Stock

4.84 USD
+0.02 (+0.41%)
Last: 8/27/2025, 8:10:40 PM
4.84 USD
0 (0%)
After Hours: 8/27/2025, 8:10:40 PM
Fundamental Rating

4

Overall ORGO gets a fundamental rating of 4 out of 10. We evaluated ORGO against 547 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. While showing a medium growth rate, ORGO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ORGO has reported negative net income.
In the past year ORGO has reported a negative cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

ORGO has a better Return On Assets (-3.38%) than 87.39% of its industry peers.
With an excellent Return On Equity value of -4.32%, ORGO belongs to the best of the industry, outperforming 89.58% of the companies in the same industry.
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROIC N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

In the last couple of years the Operating Margin of ORGO has declined.
With an excellent Gross Margin value of 74.58%, ORGO belongs to the best of the industry, outperforming 82.82% of the companies in the same industry.
ORGO's Gross Margin has been stable in the last couple of years.
ORGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.58%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ORGO has less shares outstanding
Compared to 5 years ago, ORGO has more shares outstanding
Compared to 1 year ago, ORGO has an improved debt to assets ratio.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ORGO has an Altman-Z score of 4.81. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ORGO (4.81) is better than 76.97% of its industry peers.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ORGO has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.81
ROIC/WACCN/A
WACC10.03%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.95 indicates that ORGO has no problem at all paying its short term obligations.
ORGO's Current ratio of 3.95 is in line compared to the rest of the industry. ORGO outperforms 44.79% of its industry peers.
A Quick Ratio of 3.45 indicates that ORGO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.45, ORGO is in line with its industry, outperforming 42.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.95
Quick Ratio 3.45
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ORGO have decreased strongly by -225.00% in the last year.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
The Revenue has decreased by -4.20% in the past year.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%

3.2 Future

The Earnings Per Share is expected to grow by 20.28% on average over the next years. This is a very strong growth
ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.01% yearly.
EPS Next Y-112%
EPS Next 2Y-11.68%
EPS Next 3Y20.28%
EPS Next 5YN/A
Revenue Next Year4.11%
Revenue Next 2Y6.92%
Revenue Next 3Y7.01%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ORGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 36.50 indicates a quite expensive valuation of ORGO.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaper than 90.49% of the companies in the same industry.
ORGO is valuated expensively when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 36.5
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 89.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 171.27
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ORGO's earnings are expected to grow with 20.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.68%
EPS Next 3Y20.28%

More info and screens

0

5. Dividend

5.1 Amount

ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (8/27/2025, 8:10:40 PM)

After market: 4.84 0 (0%)

4.84

+0.02 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners54.13%
Inst Owner Change7.15%
Ins Owners31.29%
Ins Owner Change0.2%
Market Cap614.00M
Analysts84.44
Price Target8.16 (68.6%)
Short Float %14.45%
Short Ratio10.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-73%
Max EPS beat(2)-73%
EPS beat(4)2
Avg EPS beat(4)278.21%
Min EPS beat(4)-73%
Max EPS beat(4)688.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.3%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)-4.23%
Revenue beat(4)2
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.38%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)6
Avg Revenue beat(16)-0.09%
PT rev (1m)14.29%
PT rev (3m)33.33%
EPS NQ rev (1m)-56.45%
EPS NQ rev (3m)200%
EPS NY rev (1m)33.33%
EPS NY rev (3m)-153.33%
Revenue NQ rev (1m)-7.85%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)1.45%
Revenue NY rev (3m)-0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 36.5
P/S 1.43
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.91
EV/EBITDA 171.27
EPS(TTM)-0.05
EYN/A
EPS(NY)0.13
Fwd EY2.74%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.39
BVpS2.85
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.58%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 74.48%
Cap/Sales 3.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.95
Quick Ratio 3.45
Altman-Z 4.81
F-Score3
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
EPS Next Y-112%
EPS Next 2Y-11.68%
EPS Next 3Y20.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%
Revenue Next Year4.11%
Revenue Next 2Y6.92%
Revenue Next 3Y7.01%
Revenue Next 5YN/A
EBIT growth 1Y-221.35%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y-140.26%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-297.24%
OCF growth 3Y-38.8%
OCF growth 5YN/A